• NEWS
  • NEWS
  • NEWS
  • NEWS
  • NEWS
  • NEWS

The latest news on XGEN and its companies.

Linkedin

Follow us on LinkedIn

  • Portfolio Company News - Press Release

Tes Pharma Announces Appointment of Andrea Pellacani, MD, PhD, as Chief Medical Officer

  • Tes Pharma
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
  • Portfolio Company News - Press Release

Professor Pellicciari Awarded by President Mattarella with the Bronze Medal of Merit for Public Health

  • Tes Pharma
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
  • Portfolio Company News - Press Release

Nouscom Appoints Seasoned Executive Eckhard Niemeier as Chief Business Officer

  • Nouscom
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
  • Portfolio Company News - Press Release

Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication

  • Nouscom
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
  • Portfolio Company News - Press Release

Gesynta Pharma forms Scientific Advisory Board with international endometriosis experts

  • Gesynta Pharma
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
  • Portfolio Company News - Press Release

AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome

  • AAVantgarde
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
  • Portfolio Company News - Press Release

Seminal new study on the role of circulating tumour-cell clusters in end-of-life cancer patients underpins strong rationale for cluster dissociation in late-stage disease

  • PAGE THERAPEUTICS
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
  • Portfolio Company News - Press Release

NanoPhoria Bioscience secures €83.5 Million Series A to Advance Breakthrough Heart Failure Therapy and Expand Portfolio for Novel Nano-in-Micro Delivery Platform

  • NANOPHORIA
NanoPhoria Bioscience, a Milan-based biotech company, today announced the successful first close of its €83.5 million Series A financing round....
  • Portfolio Company News - Press Release

Gesynta Pharma receives UK approval for a Phase 2 trial of vipoglanstat in endometriosis

  • Gesynta Pharma
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....